Nuvectis Pharma In-Licenses Exclusive Worldwide Rights to a Novel SRC/YES1 Inhibitor (NXP900) from the University of Edinburgh, Scotland
September 14, 2021 08:00 ET
|
Nuvectis Pharma, Inc.
FORT LEE, NJ , Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc., a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious...
Nuvectis Pharma Raises $15 Million and In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor from the CRT Pioneer Fund
August 26, 2021 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, New Jersey, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (the “Company” or “Nuvectis”), a biopharmaceutical company focused on the development of innovative precision medicines...